Breast Cancer Clinical Trials

Showing 5421-5440 of 5,597 trials

Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer

NCT01321775

The purpose of this study is to determine the efficacy of the combined therapy Bevacizumab, trastuzumab and paclitaxel in neo-adjuvant therapy in patients with breast cancer HER 2+ followed by surgery and adjuvant therapy (Cyclophosphamide, Trastuzumab and Doxorubicin liposomal).

Breast Cancer

Hospital Universitario Madrid Sanchinarro44 participantsStarted Aug 2009

Madrid, Madrid, Spain • Madrid, Madrid, Spain • Marbella, Malaga, Spain

COMPLETEDPhase 2

Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer

NCT00003035

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of doxorubicin with paclitaxel in treating women who have locally advanced breast cancer.

Breast Cancer

Georgetown University40 participantsStarted Mar 1997

Washington D.C., District of Columbia, United States

COMPLETEDPhase 2

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

NCT00003125

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining vaccine therapy, sargramostim, and interleukin-2 may kill more cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy, sargramostim, and interleukin-2 in treating patients who have advanced tumors.

Breast CancerEsophageal CancerGastric Cancer+3 more

Georgetown University24 participantsStarted Jan 1998

Washington D.C., District of Columbia, United States • Bethesda, Maryland, United States

Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer

Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

Related Searches

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers

Determination of Predictive Genetic Markers of Toxicity After Hypofractionated Radiotherapy in Breast Cancer Patients Post-Conservative Surgery

Do Community Cancer Support Groups Reduce Physiological Stress in Women With Primary Breast Cancer?

Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer

Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer

Trial Comparing Radioactive Seed Localization to Standard Procedure for Non-palpable Breast Cancers

Determination of Predictive Value of Echography Doppler Abnormalities

Docetaxel in Node Positive Adjuvant Breast Cancer

Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical Scanning

A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer

Faslodex Advanced Breast Cancer Local Chinese Study

Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

Collect Breast Cancer Patients' Digital Mammography Images With Corresponding Reports for the Development of Software

Efficacy of Tomosynthesis in the BIRADS 3 Population

Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

Study of Axillary Lymphadenectomy Without Drainage for Breast Cancer

Psychosocial Outcomes in Online Cancer Support Groups